Smartwatch and wearables specialist Withings has created a hybrid connected timepiece capable of taking electrocardiogram (ECG) readings over the course of an entire year.
Unlike Apple’s newest watch, which has batter power for around one day, the Withings device means wearers can monitor for atrial fibrillation, or AFib, events, for 12 months.
The watch was revealed this week at the giant consumer electronics show CES in Las Vegas.
“For the first time, an analog watch gives you the opportunity to take an ECG anytime and anywhere. With its 12-month battery life, and electrocardiogram on demand, Move ECG means you’ll never miss an AFib episode. In addition, this soon-to-be FDA-cleared device is a water-resistant activity tracker that gives you extra motivation to move more with automatic walk, run, and swim tracking plus an altimeter for stair climbing,” the company says.
AFib is the most common heart rhythm disorder in the United States, and an important warning factor for future heart failure or stroke.
No launch date was announced at CES, but the device is expected in the first quarter priced at $130.